The FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients.

Patient impairment is an expected effect from midomafetamine administration, requiring safeguards to mitigate harm for patient safety, according to FDA reviewers prior to the meeting.

FDA's proposal for MDMA involves administering the drug only in healthcare facilities with two onsite providers monitoring patients for at least eight hours post-treatment, aiming to ensure safety.

Read at Cbsnews